Clinical and cost burden of rotavirus infection before and after introduction of rotavirus vaccines among commercially and Medicaid insured children in the United States

摘要

This study aims to quantify clinical and economic burden of rotavirus (RV) infection pre- and post-vaccine introduction in commercially insured and Medicaid populations. Beneficiaries with continuous enrollment for >6 months while <5 years of age were identified separately in commercial (2000-2010) and Medicaid (2002-2009) claims databases. Commercial and Medicaid databases included 3998708 and 1 034440 eligible children, respectively, observed from enrollment start date(s) to end of eligibility or 5-years-old. Rates of RV-coded and diarrhea-coded encounters and first RV episodes, and incremental cost of first RV episodes were calculated. In the post-vaccine period, rates per 10000 person-years for RV-coded hospitalizations, outpatient visits and ER visits were 5.58 (95% Cl, 5.37-5.80), 6.96 (95% Cl, 6.75-7.20), and 4.85 (95% Cl, 4.66-5.06), respectively (pre-vaccine, 16.67 [95% Cl, 16.19-17.15], 13.20 [95% Cl, 12.78-13.63], 11.26 [95% Cl, 10.87-11.66], respectively), for commercially insured. In Medicaid the corresponding rates were 10.53 (95% Cl, 9.60-11.56), 11.72 (95% Cl, 10.73-12.80), and 9.11 (95% Cl, 8.24-10.07) (pre-vaccine, 19.78 [95% Cl, 19.14-20.45], 19.39 [95% Cl, 18.75-20.05], 27.61 [95% Cl, 26.84-28.40]). Incidence rate per 10000 person-years for first RV episode pre- vs. post-vaccine were 27.03 (95% Cl, 26.42-27.65) vs. 10.14 (95% Cl, 9.86-10.44) in the commercially insured population and 37.71 (95% Cl, 36.81-38.63) vs. 18.64 (95% Cl, 17.37-19.99) in Medicaid. Incremental per-patient per-month cost of first RV episode was dollar3363 (95% Cl, dollar3308-dollar3418) among commercially insured and dollar1831 (95% Cl, dollar1768-dollar1887) in Medicaid. Since vaccine introduction clinical burden of RV disease decreased among children; costs associated with RV episodes remained significant across insured populations.